Open a protein-vaccine example, build a response with traceable cell lineages, and compare later encounters. Then follow the separate route from vaccine mRNA to a protein.
Enable JavaScript to change the conditions and run the interactive experiment.
A vaccine supplies a starting material. Your immune system produces the response. What can persist includes experienced cell lineages and antibody-secreting cells—not a permanent store of the original vaccine.
What is supplied by the protein-vaccine example?
The documented example supplies an antigen. The recipient’s responding cell lineages produce antibodies and memory populations.
Our documented protein example uses noninfectious hepatitis B surface antigen, abbreviated HBsAg. During manufacture, engineered yeast produce the protein, which is purified and formulated with an aluminum-hydroxide adjuvant. It is a selected viral component, not a live hepatitis B virus. The adjuvant helps the immune response; it is not an antibody or a memory cell.
The immune system already contains different receptor lineages. A protein antigen can become available to matching B cells in its intact form. Antigen-presenting cells can process protein and display peptides with MHC II to compatible helper T cells. Tissue and draining lymph nodes connect these interactions.
A B cell that captures antigen can process it and present a peptide from that material. Compatible helper recognition and additional signals support the selected T-dependent response. Activated B cells divide and differentiate. Some descendants specialize in secretion; others form memory populations. The antigen itself never turns into a cell.
Plasma cells secrete antibodies. Resting memory B cells can participate in a later recall response, including generating new secretory descendants. Some plasma cells can persist and continue secretion. Turn the persistent-secretor option off: the memory record does not vanish with that display.
Choose a matching A encounter, no new encounter, or deliberately unrelated B. With earlier A memory, a matched recall route is available for A. B instead recruits another lineage in this model while the A memory remains. Both histories include ordinary innate defenses and a receptor repertoire. The unprimed comparison is not an empty immune system.
The separate mRNA view represents the platform used in mRNA COVID-19 vaccines. A delivery system helps some mRNA reach the cytoplasm, where ribosomes read it to make an antigen protein. The template and the product remain different molecules. The mRNA is later broken down; it is not inserted into nuclear DNA. This branch is not the HBsAg protein formulation.
The ENGERIX-B prescribing information, revised May 2026, documents the formulation used to ground the material explanation. Its name identifies evidence, not a recommendation or endorsement. The lesson does not model dose, administration, schedules, eligibility or individual response.
The B receptor binds intact antigen. The CD4-helper receptor recognizes an appropriate peptide–MHC II complex. The B cell can present a peptide from what it captured, linking its antigen selection with compatible help. The grouped signals control represents several prerequisites; a successful click is not a sufficient-condition prediction for a living immune system.
The model records each descendant’s parent and role. Expansion is biological cell division and differentiation, represented by a few layout icons. These counts are neither concentrations nor fixed daughter-cell yields. Resting memory cells do not emit the secretion arrows; plasma-cell descendants do.
Real B-cell responses can include germinal-center selection and maturation involving specialized helper and stromal-cell interactions. Conventional dendritic cells and follicular dendritic cells have different roles. The executable comparison omits receptor mutation, affinity selection and this detailed anatomy, rather than claiming every first antibody is a perfect fit.
The comparison records available components and necessary processes. It has no disease-outcome probability. Existing antibody can bind a matching antigen while memory reactivation and production of additional secretory descendants take separate steps. Protection depends on the vaccine, pathogen, person and measured outcome.
The mRNA delivery sequence abbreviates uptake, endosomal escape and cytoplasmic translation. Not all delivered RNA necessarily escapes or is translated. Its material is not conserved as one icon changing into a protein: cellular amino acids supply the separate product. No universal copy number, escape efficiency or half-life is assigned.
Van Damme and colleagues studied adults vaccinated against hepatitis B roughly two to three decades earlier. After a further HBsAg vaccine dose, they assessed antibody and antigen-specific cellular responses, including visits seven and thirty days later. This single-group study supports recall in its participants; it did not deliberately infect them or provide a randomized naive comparison. Its measurements do not set the animation’s timing.
Ask whether a product supplies an antigen, genetic instructions or ready-made antibodies. Those starting materials are different even when all are discussed in the language of immune protection.
A mechanism explains plausible interactions. A human study measures specified outcomes in specified participants. A rise in antibody after a vaccine challenge is not itself a direct measurement of infection prevention in everyone.
Engineered yeast can be used to manufacture purified protein outside the recipient. Cytoplasmic ribosomes can make antigen after mRNA delivery in a different platform. Keeping place, material and machinery distinct makes both routes easier to understand.
Make a pocket marked supplied antigen and put an A-protein card inside. Put separate A- and B-receptor cards in the node before opening the pocket. Antibodies and immune cells are not in the supplied-material pocket.
Use one representative intact-A card for B recognition. Use a small pA slip in an MHC II frame on a dendritic-cell card for helper recognition. A duplicate card represents another antigen copy; it does not mean a virus is replicating.
After B-A captures A, put another pA–MHC II badge on that B-cell card. Bring a compatible activated helper and the additional-signals card. Write each completed prerequisite rather than awarding points for a collision.
Branch the activated B-A lineage into plasma and memory-B descendants. Put a memory-helper badge on the T lineage. Draw antibody cards only at the plasma cell’s secretion arrow. Do not relabel the antigen as a cell.
Put away the supplied-antigen display and fold the large early-response card. Retain memory in a labeled history pocket. An optional persistent plasma-cell card can keep a separate antibody-supply arrow.
Reveal A and inspect the earlier history before building the recall route. On a parallel sheet without A history, build a naive matching response. Compare available components and required actions—not the speed of moving your hands.
Now reveal unrelated B. Keep A memory in its pocket. Use the separate B-specific repertoire for a new response. The two-shape rule omits real cross-recognition.
On another sheet, label an instruction strip mRNA and move it to a cytoplasmic ribosome outside the nucleus. Assemble a separate protein card from amino-acid marks while the template remains. Later put the instruction in a degraded pocket. Do not move it into DNA.
What stays in your history pocket when the supplied antigen card is put away?
A paper history model. No medicines, needles, biological materials, cultures or deliberate exposure. Hand-movement speed is not a measurement of immunity.
Noninfectious antigen protein The body responds to the supplied protein and generates its own adaptive response.
It provides a place for antigen-bearing cells and matching lymphocytes to interact The node connects antigen access with organized cell interactions.
Antigen-derived peptide displayed with compatible MHC II The displaying cell and peptide–MHC context matter.
A plasma-cell descendant Plasma cells specialize in secretion; memory cells participate in recall.
No, persistent cells and antibody supply are distinct components Persistent cell compartments are not computed from the number of antibody icons.
It stays, but does not execute A recall for B B can recruit another response while the A history remains.
At a ribosome in the cytoplasm Translation makes a separate protein; the instruction is later broken down.
Recorded antigen history changes the response processes available in this model This is a mechanism comparison without personal or efficacy predictions.
Section 11, Description. Noninfectious purified surface antigen produced in engineered yeast and adsorbed on aluminum hydroxide. Revised May 2026; no clinical dosing content is imported into the model.
FDA · ENGERIX-B prescribing informationInstitutional immunization education. The lesson selects a protein-dependent pathway and does not generalize schedules across vaccines.
CDC Pink Book · Principles of VaccinationUse the separately identified antigen, subunit and adjuvant sections; no mismatched whole-microbe wording is copied.
WHO · What’s in a vaccine?Institutional mRNA COVID-19 mechanism explanation. No genome-insertion step, fixed molecule lifespan or current recommendation is inferred.
CDC · COVID-19 vaccine mechanismsOriginal mouse imaging study, not a human HBsAg-vaccine timing parameter.
Miller et al. · lymph-node imagingOriginal human B/T-clone experiments preserve the distinct recognition targets.
Lanzavecchia · Nature, 1985Original mouse imaging, antigen-engaged B-cell relocation and cognate contacts. No source migration speed is assigned to this lesson.
Okada et al. · PLOS Biology, 2005Adults in a phase IV single-group vaccine-challenge study; antibody and cellular responses, not deliberate infection or a randomized naive comparison. DOI 10.1111/jvh.13125.
Van Damme et al. · Journal of Viral Hepatitis, 2019Original rhesus-macaque study after memory-B-cell depletion. Species and experimental context are retained.
Hammarlund et al. · Nature Communications, 2017Original BNT162b2 study of germinal-center maturation, memory and plasma compartments. Its observations do not become a universal vaccine trajectory.
Kim et al. · Nature, 2022Institutional qualitative mechanism explanation; no illustrated duration is adopted as a model constant.
WHO Europe · How vaccines workPDB 8YMJ, assembly 1: 80 protein chains already present, reported 6.6 Å reconstruction. Wang et al., Science 2024, DOI 10.1126/science.adp1453. Recombinant HEK293F research expression, distinct from the documented formulation.
RCSB PDB · 8YMJPDB 8YMK, assembly 1: two S-HBsAg chains, reported 3.7 Å localized reconstruction. A dimer is not the complete particle.
RCSB PDB · 8YMKPDB data CC0. Local manifests retain hashes, chain identity, common coordinate transforms and mesh processing.
wwPDB · usage policyRyan Kissinger / NIAID Visual & Medical Arts, NIH BioArt Source. Individual image entries and public-domain provenance are linked beside the model.
NIH BioArt Source · B-cell illustrationIndependent subject review is pending.
Read the sources and model assumptions
Interactive explorationFollow a message from skin to lymph node, match two kinds of recognition, and inspect an actual antibody structure. Then discover what immune memory can leave ready.
Interactive explorationTake apart a human ribosome, follow a message three letters at a time, then change a DNA base and discover what the peptide does.
Interactive explorationTurn a real anatomical model in your hands. Reveal its chambers, meet the four valves, then follow the blood moving through both sides of the heart.